Ellen J. Scherl, M.D.
Ellen J. Scherl, M.D. is the Director of The Roberts Center for Inflammatory Bowel Disease, The Jill Roberts Professor of Clinical Medicine, Sanford I. Weill College of Cornell University - New York Presbyterian Hospital. She is currently an Attending Physician at the New York Presbyterian Hospital-Weill Medical College of Cornell University.
Dr. Scherl is a world-renowned expert in InflammatoryBowel Disease specializing in Crohn's Disease and Ulcerative Colitis. Dr. Brian Bosworth and Dr. Vinita Jacob are also part of The Roberts Inflammatory Bowel Disease Center and work closely with Dr. Scherl. Dr. Scherl has an active practiceand serves as a principal investigator on many clinical trials on Crohn's Disease and Ulcerative Colitis. As part of Dr. Scherl's comprehensive approach to patient care, she closely collaborates with world renowned IBD surgical team leadby experts Dr. Fabrizio Michelassi and Dr. Jeffrey Milsom, complimented by Dr. Toyoki Sonoda, and Dr. Sang Lee.The team is known for innovative surgical approaches including laproscopic and endoscopic techniques as well as bowelsparing surgeries. The IBD center also works closely with Dr. Robbyn Sockolow, the director of the Pediatric GastroenterologyDivision and who also has an active pediatric IBD practice. Dr. Arun Swaminath, and Dr. Oscar Lebwohl of The New YorkPresbyterian Hospital - Columbia Campus also work closely with Dr. Scherl in her efforts.
The Roberts Centerfor Inflammatory Bowel Disease is exploring ways of intergrating healthcare and IBD research looking forward to achievingpreventive and personalized medicine. The IBD Center is committed to the interdisciplinary approach to Inflammatory Bowel Disease focusing on nutrition, osteoporosis, nephrology, dysplasia, and colon cancer screening using novel techniquessuch as narrow band imaging. Dr. Scherl frequently lectures on Inflammatory Bowel Disease at local, regional and nationalmeetings, conferences and seminars.
Dr. Scherl has an active practice and serves as a principal investigator on many clinical trials involving innovative and investigational therapies for Ulcerative Colitis and Crohn's Disease. She has established an IBD tissue bank at Weill Medical College of Cornell University/New York-Presbyterian Hospital, has collaborated with researchers at Cornell University to identify a novel E. Coli bacteria associated with Crohn's Disease and continues to collaborate with Weill Medical College of Cornell University/New York-Presbyterian Hospital researchers investigating the immunogenetics and pathobiology of IBD. As part of Dr. Scherl's comprehensive approach to patient care , she closely collabrates with Dr. Michelassi, Milsom, Sonoda, and Lee who are part of the internationally renowed and innovative IBD group of surgeons.
Dr. Scherl is an editorial reviewer for the IBD Journal, Journal of Clinical Gastroenterology, Gastrointestinal Endoscopy, and Gastroenterology and Hepatology. Also, she is co-editing The Changing World Of IBD and co-authorizing a comprehensive IBD text-book. She is the author of numerous peer-reviewed articles and book chapters.
She recently received the 2008 AGA award for Outstanding Women In Science and in 2007 was awarded the NYSGE Florence Lefcourt Distinguised Service Award.
Currently, Dr. Scherl is a Fellow of the American College of Physicians ( FACP), American Gastroenterological Associate Fellow (AGAF) and a member of numerous professional societies. She is a Board member and the Education Director for Women and IBD: WE CARE, The Chair for the Chapter Medical Advisory Committee for the CCFA and she also is on the Advisory Board for the GI Health Foundation, www.ibdcme.tv. She frequently lectures on Inflammatory Bowel Disease at local, regional, and national meetings, conferences and seminars. She is exploring ways of integrating healthcare and IBD research looking towards achieving preventive and personalized medicine.
Insurance Plans Accepted
The following represents most of the managed care plans accepted by this physician. If your insurance carrier does not appear here please contact the physician’s office as they may have individual contracts not included on this site.
* indicates this physician is no longer accepting new patients with this insurance plan.
- AETNA [PPO]
- AETNA [HMO]
- Aetna - Weill Cornell [POS]
- Blue Priority Network
- Empire Blue Cross/Blue Shield [Pathway X]
- Empire Blue Cross/Blue Shield [PPO]
- Empire Blue Cross/Blue Shield [Pathway X Enhanced]
- Empire Blue Cross/Blue Shield [Mediblue (Senior)]
- Empire Blue Cross/Blue Shield [EPO]
- Empire Blue Cross/Blue Shield [HMO]
- Health First
- Health Plus - Amerigroup [CHP]
- Health Republic
- Oxford Health Plans [Freedom]
- Rockefeller University - CoreSource
- United Health Care
Peer Reviewed Articles:
1. Thung SN, Scherl E, Gerber MA. Hepatitis In Patients With AIDS. Hepatology, 3 (5): 864-864
2. Scherl EJ, Fabry TL. Pseudodiverticula Secondary To Injection Sclerotherapy. Journal of
Clinical Gastroenterology, 5 (5): 401-403 1983.
3. Cohen LB, Korsten MA, Scherl EJ, Velez ME, Fisse RD, Arons EJ. Bacteremia After
Endoscopic Injection Sclerosis. Gastrointestinal Endoscopy, 29 (3):198-200 1983.
4. Simon C, Cohen L, Scherl E, Waye JD, Korsten MA. Esophageal Motility And Symptoms After
Endoscopic Injection Sclerotherapy. Gastrointestinal Endoscopy, 29 (2): 192-192 1983.
5. Scherl EJ, Fabry TL. Pseudodiverticula After Esophageal Sclerotherapy. Gastrointestinal
Endoscopy, 29 (2): 192-192 1983.
6. Scherl E, Siegel F, Geller S, Waye J. Gastrointestinal Manifestations Of Acquired
Immunodeficiency Syndrome (AIDS). Gastroenterology, 86 (5): 1235-1235 1984.
Waitman AM, Grant DZ, Scherl EJ, Chateau FZ. Laser Endoscopy - Beth-Israel Experience 250
Patients. Gastrointestinal Endoscopy, 31 (2): 160-161 1985.
7. Cohen LB, Simon C, Korsten MA, Scherl EJ, Skorniky J, Guelrud MB, Waye JD. Esophageal
Motility And Symptoms After Endoscopic Injection Sclerotherapy. Digestive Diseases And
Sciences, 30 (1): 29-32 1985.
8. Waitman AM, Grant DZ, Scherl EJ, Brettholz EM, Chateau F. Neodynium-Yag (Nd-
Yag) Laser In The Treatment of 78 Patients With Malignant Dysphagia. Gastrointestinal
Endoscopy, 34 (2): 183-184 Mar-Apr 1988.
9. Bayless T, Drossman D, Scherl EJ. Helping Your IBD Patient Help Himself. Patient Care; Oct
15 1988: 139-156.
10. Grant D, Scherl EJ, Waitman A, and Chateau F. Laser Therapy and Vascular Abnormalities.
Therapeutic Gastrointestinal Endoscopy 1990; Steven Silvis (Ed):151-174.
11. Kelfen D, Laufer I, Leichman L, Orringer M, Rich T, and Scherl EJ. Alarming Trends in
Esophageal Carcinoma. Patient Care; Oct 15, 1992: 72-122.
12. Goldman IS, Snady H, Waye JD, Scherl E, Morrissey K, Forde KA. Cecal photo-documentation:
Reliable when you are there, unreliable when you are not. Gastrointestinal Endoscopy, 43 (4):
301-301 Apr 1996
13. Scherl E. The mysteries within: A surgeon reflects on medical myths.
American Book Review, 22 (2): 28-28 Jan-Feb 2001.
14. Friedman S, Marion JF, Scherl EJ, Rubin P, Present DH. Intravenous Cyclosporine For
Refractory Pyoderma Gangrenosum Complicating Inflammatory Bowel Disease.
Inflammatory Bowel Diseases, 7 (1): 1-7, Feb 2001.
15. Persley K, Scherl E, Rubin P. Avoidance of steroids by the early use of infliximab and 6-
mercaptopurine in an adolescent with active Crohn's colitis. American Journal of
Gastroenterology, 96 (12): 3444-3445 Dec 2001
16. Chutkan RK, Scherl E, Waye JD. Colonoscopy in inflammatory bowel disease.
Gastrointest Endosc Clin N Am. 2002 Jul;12(3):463-83, viii. Review.
17. Scherl EJ. Irritable-inflammatory bowel disease: recognizing a new overlap syndrome
and an enigma wrapped inside a puzzle. Inflamm Bowel Dis, 8(5):373-4 Sep 2002.
18. Scherl, E, Subbaramaiah, K. Optimization and Individualization of Thiopurine Therapy
In Inflammatory Bowel Disease: The Great Variability Among Drug Responses. Pharmacogenomics Journal, 3: 66-68, 2003.
19. Scherl, E, Frissora, CL. Irritable Bowel Syndrome Genophenomics: Correlation of Serotonin-
transporter Polymorphisms and Alosetron Response. Pharmacogenomics Journal, 3: 64-65,
20. Subbaramaiah K, Yoshimatsu K, Scherl E, Das KM, Glazier KD, Golijanin D, Soslow
RA, Tanabe T, Naraba H, Dannenberg AJ. Microsomal prostaglandin E synthase-1 is
over expressed in inflammatory bowel disease. Evidence for involvement of the
transcription factor Egr-1. Epub Jan 1 2004. J Biol Chem, 279(13):12647-58, Mar 26
21. Moskovitz DN, Bodian C, Chapman ML, Marion JF, Rubin PH, Scherl E, Present DH.
The effect on the fetus of medications used to treat pregnant inflammatory bowel-disease patients.
Am J Gastroenterol, 99(4):656-61, Apr 2004.
22. Nilubol N, Scherl E, Bub DS, Gorfine SR, Marion J, Harris MT, Kornbluth A, Lichtiger
S, Rubin P, George J, Chapman M, Harpaz N, Present D, Tejero C, Bodian C, Bauer JJ.
Mucosal dysplasia in lleal pelvic pouches after restorative proctocolectomy. Diseases of
The Colon & Rectum, 48 (3): 627-628 Mar 2005
23. Thevarajah S, Polaneczky M, Scherl EJ, Frissora CL. Hormonal Influences on the
Gastrointestinal Tract and Irritable Bowel Syndrome. Practical Gastroenterology,
Treatment of Irritable Bowel Syndrome, Series #7: 62 Â 74, May 2005.
24. Yang A, Chen Y, Scherl E, Neugut AI, Bhagat G, and Green PHR. Inflammatory
Bowel Disease in Patients with Celiac Disease. Inflammatory Bowel Diseases, 11 (6): 528 Â 32
25. Jahraus CD, Rubin DT, Scherl EJ, Bettenhausen D. InflammationÂs Role in Rectal
Cancer Following Prostate Radiotherapy, and Emerging Evidence for a Protective Role
for Balsalazide. Gastroenterology, 129 (2): 770 Â 772 Aug 2005.
26. Schwartz LK, Kim MK, Coleman M, Lichtiger S, Chadburn A, Scherl E. Case Report: Lymphoma Arising in an Ileal Pouch Anal Anastomosis After Immunomodulatory Therapy for Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology 2006, 4:1030-1034. August 2006.
27. Poppers D, Scherl E. Evolution in the Pharmacogenetics and Pharmacogenomics of Inflammatory Bowel Disease Â Order Slowly Rises from the Chaos. Current Pharmacogenomics; September 2006.
28. Present DH, Lichtenstein GR, Scherl EJ. Emerging Issues in Ulcerative Colitis and Proctitis.
Gastroenterology and Hepatology, vol. 2 (9), supp. 11; Sept 2006.
29. Nilubol N, Scherl E, Bub DS, Gorefine SR, Marion J, Harris MT, Kornbluth A, Lichtiger S, Rubin P, George J, Chapman M, Harpaz N, Present D, Bauer J. Mucosal Dysplasia in Ileal Pelvic Pouches after Restorative Proctocolectomy. Diseases of the Colon & Rectum; Winter 2006.
30. Scherl E., Review in Inflammatory Bowel Diseases, Selected Summaries. Bacteria, Bugs, and BID Rifaximin for CrohnÂs Disease, P.1-2.
31. Lichtenstein, GR., Scherl E. 5-ASA Therapy in Management of Ulcerative Colitis Patients, Gastroenterology and Hepatology, Volume 3, Issue 3, Supplement 11, p.3-16; March 2007.
32. Scherl E. 5-ASA Pharmacokinetics, Gastroenterology and Hepatology, Volume 3, Issue 3, Supplement 11, p.7-8; March 2007.
1. Scherl, EJ, and Fabry, T, "Pseudodiverticula Post Sclerotherapy". Abstract in Journal of Clinical
Gastroenterology; 5:401-403, 1983.
2. Simon, C, Cohen, L, Scherl, EJ, Waye, JD, Korsten, M. Esophageal Motility Following Injection Sclerotherapy. Gastrointestinal Endoscopy May 1983; Abstract.
3. Rubin PH, Chapman ML, Scherl E, Sachar DB, Stamaty C, Present DH. Clarithromycin in active Crohn's disease (CD): Preliminary results of open label pilot study. Gastroenterology, 110 (4): A1005-A1005 Suppl. S Apr 1996.
4. Friedman S, Marion JF, Scherl E, Rubin P, Present DH. The treatment of choice for pyoderma
gangrenosum complicating IBD - Intravenous Cyclosporine. Gastroenterology, 112 (4): A975-
A975 Suppl. S Apr 1997
5. Toy LS, Campbell NA, Weiss AA, Scherl EJ, Mayer L. Defective gp180 expression in
the buccal mucosa of patients with ulcerative colitis but not with Crohn's disease.
Gastroenterology, 114 (4): G4504 Part 2 Suppl. S Apr 15 1998.
6. Korzenik JR, Robert ME, Bitton A, Robinson M, Scherl EJ, Fisher RL, Binder HJ. A multi-center, randomized, controlled trial of heparin for the treatment of ulcerative colitis. Gastroenterology, 116 (4): G3264 Part 2 Apr 1999.
7. Toy LS, Scherl EJ, Kraus TA, Mayer L. Defective GP180 expression in mono-zygotic twins
discordant for ulcerative colitis. Gastroenterology, 116 (4): G3619 Part 2 Apr 1999.
8. Toy LS, Marion JF, Scherl EJ, Chapman ML, Present DH. Short term Infliximab toxicity in Crohn's disease. Gastroenterology, 118 (4): 2973 Part 1 Suppl. 2 Apr 2000.
9. Toy LS, Scherl EJ, Kornbluth A, Marion JF, Greenstein AJ, Agus S, Gerson C, Fox N, Present DH. Complete bowel obstruction following initial response to Infliximab therapy for Crohn's disease: A series of a newly described complication. Gastroenterology, 118 (4): 2974 Part 1 Suppl. 2 Apr 2000.
10. Toy LS, Marion JF, Scherl EJ, Chapman ML, Bodian C, Present DH. Infliximab therapy for Crohn's disease fistulae: Number of infusions required for response and time to relapse. Gastroenterology, 118 (4): 2975 Part 1 Suppl. 2 Apr 2000
11. Marion JF, Bodian C, Lisa T, Chapman ML, Scherl EJ, Present DH. TNF micro-satellite
Polymorphism does not predict response to infliximab in patients with Crohn's disease.
Gastroenterology, 118 (4): 3596 Part 1 Suppl. 2 Apr 2000.
12. Nilubol N, Bauer JJ, Gorfine SR, Scherl E, Kornbluth AA, Lichtiger S, Rubin PH, George J,
Chapman ML, Harpaz N, Tejero C, Present DH. In search of ileal mucosal dysplasia: A
prospective study of 138 pelvic pouch patients recalled one or more years following restorative
proctocolectomy. Gastroenterology, 120 (5): 2405 Suppl. 1 Apr 2001.
13. Moskovitz D, Scherl EJ, Chapman ML, Marion JF, Rubin PH, Present DH. 5-ASA Drugs
Metronidazole, Ciprofloxacin, Prednisone, 6 Mercaptopurine and Azathioprine use
in Pregnant Patients with Inflammatory Bowel Disease. Journal of American College of
Gastroenterologists; abstract in press.
14. Lodhavia PJ, Scherl EJ. Efficacy of infliximab in the treatment of refractory pouchitis. American Journal of Gastroenterology, 97 (9): 548 Suppl. S Sep 2002.
15. Kim MK, Scherl E, Coleman M. Lymphoma of the pouch after IPAA for medically refractory ulcerative colitis. American Journal of Gastroenterology, 99 (10): S184-S184 568 Suppl. S Oct 2004
16. Bosworth BP, Schnoll-Sussman F, Scherl, E. Video capsule endoscopy diagnosis of oxaliplatin-
induced enteritis in a patient with X-ray negative Crohn's disease. American Journal of
Gastroenterology, 99 (10): S186-S187 Suppl. S Oct 2004.
17. Bosworth BP, Scherl EJ. A novel non-absorbable antibiotic (rifaximin) in the treatment of moderate to severe Crohn's disease. Gastroenterology, 128 (4): A576-A576 Suppl. 2 Apr 2005
18. Weine DM, Bosworth BP, Poppers DM, Scherl EJ. The Role Of Serologic Markers In Predicting Infliximab Response In Ulcerative Colitis. Gastroenterology, submitted for DDW Supp Apr 2006.
19. Scherl EJ. The Gut-Selective Antibiotic Rifaximin in the Treatment of Refractory Solitary Rectal
Ulcer: A Case Report. Gastroenterology, submitted for DDW Supp Apr 2006.
20. Sandborn, W., Fagan, B, Fedorak, R., Scherl, E., Fleischer, M., Katz, S., Johanns, J., Blank, M., Rutgeertz, P. A Multicenter Randomzed Phase 2A Study of Human Monoclonal Antibody to IL-12/23 p40 (Cnto1275) in Patients with Moderately to Severely Active CrohnÂs Disease. Gastroenterol, 2007: 132;4 (Suppl 2) A272 (Page A-51).
Books, Book Chapters and Reviews:
1. Scherl EJ, Sachar DB. Crohn's Disease of the Small Intestine. Gastroenterology and Hepatology: The Comprehensive Visual Reference, Series ed. Mark Feldman. Churchill Livingston Ford LVA 1997; 7.1-7.22.
2. Scherl E, Weine D, etal. Pocket Guide to Inflammatory Bowel Disease. eds. Sunanda Kane,
University of Chicago and Marla Dubinsky, Cedars Sinai Medical Center. Cambridge University
3. Scherl EJ, Weine DM, Bosworth B, Green PH. Medical Therapy of Gastroduodenal CrohnÂs Disease. In: Lichtenstein GR, ed. Inflammatory Bowel Disease: The complete
guide to medical management. Slack, Inc. (in press).
Honors and Awards
CrohnÂs and Colitis Foundation of America Woman of Distinction 1995
NYSGE Florence Lefcourt Distinguished Service Award January 2007
ÂDoes the Degree of Endoscopic Severeity in Patients with CrohnÂs
Disease Correlate with Pathologic Findings on Mucosal Biopsy
Specimens?Â Mendelsohn, R.B., Bramlage, M., Makhoul, Y.,
Scherl, EJ, Yantiss, R., and Bosworth, B.P.
This was presented as a combination of the Division of the Roberts
Center for IBD, the Division of Gastroenterology and Hepatology at
New York Presbyterian Hospital, Weill Cornell Medical Center, the
Division of Pathology and Laboratory Medicine, and Staten Island
University Hospital, Staten Island, New York. This received
Honorable mention or poster of distinction by Weill Cornell
Medical Center. May 2007
- Crohn's Disease
- Inflammatory Bowel Diseases (IBD)
- Ulcerative Colitis
- Clinical Research
- Internal Medicine
- M.D., New York Medical College, 1977